Nanosuspension formulation of itraconazole eliminates the negative inotropic effect of SPORANOX in dogs.
about
Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailabilityEpidemiology and treatment approaches in management of invasive fungal infectionsAssociation of systolic blood pressure drop with intravenous administration of itraconazole in children with hemato-oncologic diseaseDevelopment of PLGA-based itraconazole injectable nanospheres for sustained release.
P2860
Nanosuspension formulation of itraconazole eliminates the negative inotropic effect of SPORANOX in dogs.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Nanosuspension formulation of ...... ic effect of SPORANOX in dogs.
@en
Nanosuspension formulation of ...... ic effect of SPORANOX in dogs.
@nl
type
label
Nanosuspension formulation of ...... ic effect of SPORANOX in dogs.
@en
Nanosuspension formulation of ...... ic effect of SPORANOX in dogs.
@nl
prefLabel
Nanosuspension formulation of ...... ic effect of SPORANOX in dogs.
@en
Nanosuspension formulation of ...... ic effect of SPORANOX in dogs.
@nl
P2093
P2860
P1476
Nanosuspension formulation of ...... ic effect of SPORANOX in dogs.
@en
P2093
Barrett Rabinow
Chyung Cook
Jeff McKee
Jerry Gass
P2860
P2888
P304
P356
10.1007/S13181-010-0025-6
P577
2010-09-01T00:00:00Z